Cancer Treatment News and Research

RSS

British Pharmacological Society celebrates the start of annual meeting

The British Pharmacological Society (BPS) today celebrated the start of its annual meeting, which will cover the latest research in drug discovery over the next three days, including a special focus on discoveries in cancer treatment.

19 Dec 2012

Myostatin responsible for initiation of muscle loss: Study

A research study from Nanyang Technological University (NTU) has yielded important breakthroughs on how the body loses muscle, paving the way for new treatments for aging, obesity and diabetes.

19 Dec 2012

New report provides snapshot of Canada's cancer system

A comprehensive report released today by the Canadian Partnership Against Cancer provides a snapshot of how Canada's cancer system is performing in key areas from prevention through to patient experience and outcomes.

17 Dec 2012

New diagnostic innovations could refine the way doctors detect prostate cancer

Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations – the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it.

15 Dec 2012

At-home exercise regimen sufficient to increase cancer patients' mobility and reduce fatigue

It has been known for some time that exercise is important for cancer patients, but few studies have looked at the practicality of exercise programs and whether even a minimal workout can help.

14 Dec 2012

Opioids already in the body can enhance malignant tendencies of human cancer cells

A study led by University of Chicago researcher Patrick A. Singleton, Ph.D. and published in the journal Anesthesiology has shown that, even without the addition of further opioids such as morphine, opioids already in the body can enhance the malignant tendencies of human cancer cells.

13 Dec 2012

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology - "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy."

13 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

Childhood obesity: an interview with Professor Clodagh O’Gorman

Childhood obesity is harder to define than adult obesity. This is because any definition of obesity relies on measurements of both height and weight, and the calculation of body mass index (BMI) based on these measurements.

10 Dec 2012

Ex-con gets arrested on purpose in order to get health care

A 56-year-old ex-convict says he purposely got arrested for shoplifting to get prison health care for his leukemia.

10 Dec 2012

First Edition: December 10, 2012

Today's headlines include news about yesterday's "fiscal cliff" meeting between President Barack Obama and House Speaker John Boehner, as well as other health policy reports.

10 Dec 2012

GSK, MD Anderson partner to develop new therapeutic antibodies against cancer

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer.

10 Dec 2012

Positive results from NanoString's second clinical study of PAM50-based breast cancer assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostic products, today announced positive results from the second clinical validation study of its in vitro diagnostic breast cancer assay based on the PAM50 gene expression signature.

From NanoString Technologies 7 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

ASBD to host 6th Annual School of Oncoplastic Surgery in Dallas

The American Society of Breast Disease (ASBD) is merging art and medicine this week, by using clay sculpting and other techniques to teach surgeons new skills in breast cancer surgery and reconstruction.

6 Dec 2012

CPRIT announces new grants to support variety of cancer-fighting research projects in Texas

The Cancer Prevention and Research Institute of Texas (CPRIT) today announced more than $85 million in funding to support 75 new scientific research projects and scientific recruits to support a variety of cancer-fighting efforts in Texas. These new awards bring the total tally of funded grants to 502, amounting to nearly $841 million since the Institute opened its doors in 2009.

6 Dec 2012

National Radiation Oncology Registry program for quality assessment and improvement

The National Radiation Oncology Registry (NROR) pilot program will serve as the basis for the creation of a nationwide electronic registry to capture reliable, population-based information on radiation treatment delivery and health outcomes and will be supported by an innovative information technology (IT) infrastructure that will maximize efficiency through the automated collection and electronic transfer of data, according to research presented at the American Society for Clinical Oncology (ASCO) Quality Care Symposium.

5 Dec 2012

Arthrobotrys oligospora produces nanoparticles that could kill tumors

Arthrobotrys oligospora doesn't live a charmed life; it survives on a diet of roundworm. But a discovery by a team led by Mingjun Zhang, an associate professor of biomedical engineering at the University of Tennessee, Knoxville, could give the fungus's life more purpose-as a cancer fighter.

5 Dec 2012

Certain patients with prostate cancer may benefit from Provenge clinical trial

Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

4 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012